CBLL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.47%, SMA50 -8.54%, SMA200 18.95%). The stock’s 14-day RSI is 40.99 (neutral), while the ATR of 1.0 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.37% below its high and over 93.71% above its low. Average 10-day trading volume of 325.52 thousand shares is below the 3-month average of 363.80 thousand, indicating normal recent market interest.

CeriBell, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $55.69. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 16.28% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $17.00. The high target offers 64.38% upside. The low target suggests -6.85% downside. The mean target is $24.43. This offers 33.86% upside. CeriBell, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 33.33%. The prior quarter beat by -16.28%. Over the last six quarters, Apple has recorded several small beats. These include 25.0% in February 25, 2025.

CeriBell, Inc. has 37.94 million shares outstanding. The public float is 26.06 million shares, elevated short interest at 7.51% of float. This equals 1.85 million shares. The short ratio is 4.72 days. Institutional investors hold 99.61% of the float. Insiders own 12.79%. TPG GP A, LLC holds 3.77 million shares, Chao Xingjuan has 788.32 thousand shares and Parvizi Josef has 722.65 thousand shares. Over the past six months, insider transactions show net selling. They sold 404.74 thousand shares across 29 transactions.

CeriBell, Inc. (NASDAQ:CBLL) closed at $18.47 USD, gaining $0.22 (1.21%) from the previous close of $18.25. The stock is currently mid-range between its 52-week high and low $10.85 and $24.33. With a market capitalization of about $700.80 million, CeriBell, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.81). Key stats such as the average daily volume over the past year has been around 371.41 thousand shares, volume is running light vs its 52-week average. Headquartered in Sunnyvale, CA, CeriBell, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Xingjuan Chao, the company employs approximately 327 people and listed since October 11, 2024. CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside.

CeriBell, Inc. trades at a P/E ratio of -11.23, slightly below the S&P 500 average, with a price-to-sales ratio of 7.31 and a price-to-book ratio of 4.9 trading at moderately above to book value. The P/FCF stands at -13.85, also above market averages.

CeriBell, Inc. (NASDAQ:CBLL) shares are flat -2.19% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CeriBell, Inc. trading at a premium to the broader market with a P/E of -11.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.73, suggesting 51.95% upside. Our AI forecast model points to short-term weakness (-5.21% over two weeks), a medium-term fall (-23.4% over three months), and a longer-term loss (-17.48% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CeriBell, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.21%, with price expected at $17.30 by August 20, 2026, within a range of $16.46 to $18.15 3-Month Outlook: Projected fall of -23.4%, reaching $13.98 by November 04, 2026, with a range of $13.40 to $14.50. 1-Year Outlook: Projected loss of -17.48%, with price at $15.06 by August 06, 2027, within a range of $13.76 to $16.75.